CELZ
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
NASDAQ · Healthcare · Biotechnology · US
$0.72
−2.35%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$0.75
From 52W high−87.06%
Volume95314.00
Market cap$5.49M
P/E (TTM)—
P/S (TTM)1831.3x
Div yield—
Key dataOct 19, 2026
Open
$0.75
From 52W high
−87.06%
Volume
95314.00
Market cap
$5.49M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.5x
P/E (TTM)
—
RSI (14)
33.2
MomentumView details →
1D Return
−2.35%
YTD Return
−62.02%
SummaryUpdated Jun 1, 2026
Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) is a biotechnology company founded in 2015 and based in Phoenix, Arizona. The company focuses on developing adult stem cell treatments across multiple medical specialties including immunology, urology, orthopedics, and neurology. Since going public in November 2015, CELZ has been in the clinical development stage, working to advance its portfolio of stem cell-based therapies for various medical conditions ranging from erectile dysfunction to stroke recovery.
Similar companies
Latest newsMore news →
Creative Medical Technology Holdings, Inc. acquired 4,000,000 shares of BioDefense, Inc. common stock from Creative Acquisition Corp. for $200,000 in cash and 1,000,000 shares of its own common stock, giving it an 80% ownership stake.24d agoCreative Medical Technology Holdings filed a new U.S. provisional patent application to expand intellectual property protection for its Ultrasome cell-free regenerative medicine platform.33d agoCreative Medical Technology Holdings completed enrollment and treatment of all patients across its FDA-cleared ADAPT clinical trial for CELZ-201/Olastrocel, including the opioid expansion cohort, advancing the therapy toward RMAT evaluation and Phase 3 planning for chronic lower back pain.61d ago